Product News

Share this article:
GlaxoSmithKline says the US launch of HPV vaccine Cervarix will feature a slightly lower price than that of Merck's vaccine Gardasil, the Financial Times reports. GSK's new entrant will carry a wholesale cost of $386 for a three-course dose, compared with $399 for rival Gardasil, making the GSK vaccine more attractive for payers. The price strategy already has helped GSK win a vaccine contract in the UK.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions